Finance

Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
$9.08
0.00%
(0.00) 1D
$9.21
+1.43% (+0.13)
After hours
Closed: Aug 21, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
$9.19
High
$9.44
Low
$9.03
Mkt. cap
727.98M
Avg. vol.
295.88K
Volume
171.56K
52-wk high
$14.87
52-wk low
$7.01
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
Open
$9.19
High
$9.44
Low
$9.03
Mkt. cap
727.98M
Avg. vol.
295.88K
Volume
171.56K
52-wk high
$14.87
52-wk low
$7.01
EPS
-$3.04
Shares outstanding
80.17M
No. of employees
88
News stories
From web sources and news partners
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees88
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitebbotx.com
Analyst ratings
Based on 6 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current $9.08
$25.00 (+175.33%)
Average
$22.33 (+145.93%)
Lowest
$18.00 (+98.24%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sean Laaman
Morgan Stanley
Buy
Reiterated
$18.00
+98.2%
08/17/2026
Unknown Analyst
J.P. Morgan
Buy
Reiterated
$25.00
+175.3%
08/14/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
$25.00
+175.3%
08/14/2026
Unknown Analyst
Wedbush
Buy
Initiated
$25.00
+175.3%
08/12/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$22.00
+142.3%
08/12/2026
John Newman
Canaccord Genuity
Buy
Reiterated
$23.00
+153.3%
08/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
$21.00
+131.3%
08/12/2026
David Nierengarten
Wedbush
Buy
Maintained
$25.00
+175.3%
05/13/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$23.00
+153.3%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$22.00
+142.3%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+219.4%
05/01/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$41.00
+351.5%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
35.05M
38.07M
39.80M
49.22M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
14.13M
5.33M
6.38M
10.96M
Operating expense
49.18M
43.41M
46.18M
60.19M
Total operating expenses
49.18M
43.41M
46.18M
60.19M
Operating income
-49.18M
-43.41M
-46.18M
-60.19M
Other non operating income
980.00K
187.00K
129.00K
182.00K
EBT including unusual items
-44.76M
-38.80M
-42.11M
-56.45M
EBT excluding unusual items
-44.76M
-38.80M
-42.11M
-56.45M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-44.76M
-38.80M
-42.11M
-56.45M
Net profit margin
-
-
-
-
Earnings per share
-1.03
-0.49
-0.53
-0.71
Interest and investment income
3.44M
4.42M
3.94M
3.55M
Interest expense
-
-
-
-
Net interest expenses
3.44M
4.42M
3.94M
3.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-49.11M
-43.32M
-46.10M
-60.11M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps